BioSpace News Archive

Ascentage Pharma has recommended the novel candidate drug olverembatinib (HQP1351) of Guangzhou Healthquest Pharma Co.

Patients with mild-to-moderate Alzheimer’s disease (AD) receiving Leukine experienced significant reversal of cognitive loss and biomarkers of disease progression while taking Leukine Study shows Leukine safe and tolerable and concludes that the innate immune system is a viable target for therapeutic intervention in AD

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the appointment of Saraswathy (“Sara”) Nochur, Ph.D., to its Board of Directors.

Bruker Corporation (Nasdaq: BRKR), a leading supplier of single-plane illumination microscopy (SPIM) technology for research on live cells and cleared biological samples, today announced that two Luxendo MuVi™ and LCS SPIM™ light-sheet microscopes have been installed by Memorial Sloan Kettering Cancer Center (MSK).

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of William Mezzanotte, MD, MPH to its Board of Directors.

Second Sight Medical Products, Inc. (NASDAQ: EYES), (the “Company” or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it has entered into definitive securities purchase agreements with accredited investors for a private placement that will result in gross proceeds to Second Sight

DehydraTECH TM CBD-Beverage Demonstrates 93.4% Potency One Year After Production Lexarias Nanoemulsification Processing Technique Ensures Content Uniformity and Homogeneity of CBD Distribution Without Need for Physical Mixing

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that it will host a webcast and conference call on Tuesday, March 30, 2021 at 4:30 p.m. ET

- CAR T-cell therapy manufacturing commenced with Iomab-ACT conditioning and patient treatment scheduled for early Q2:2021 - Clinical proof-of-concept data expected in 2H:2021 from first of its kind trial funded by NIH STTR grant

Abcam, a global innovator in life science reagents and tools, announced that Dr Alejandra Solache, SVP of Research & Development received the CiteAb award for ‘Significant Individual Impact’ and the Company was recognized as ‘Antibody Supplier Succeeding in Cardiovascular Research’.